Why is it hard to terminate failing projects in pharmaceutical research and development?
'Quick-kill' strategies in pharmaceutical research and development aim to reduce late-stage attrition by bringing project termination decisions forward, to an earlier point in the process. Here, Dennis Lendrem and colleagues consider how the barriers to implementing such strategies can be overcome.
Please sign in or register for FREE
Sign in to BioPharma Dealmakers
Register to BioPharma Dealmakers
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.